Survey of medical oncologists and trainee practice on venous thromboembolism prophylaxis and treatment in solid cancers

James Yeung; Angelina Tjokrowidjaja; Craig Lewis; Jodi Lynch

doi:10.1111/imj.15984

Survey of medical oncologists and trainee practice on venous thromboembolism prophylaxis and treatment in solid cancers

Intern Med J. 2023 Jan;53(1):131-135. doi: 10.1111/imj.15984.

Authors

James Yeung^{1

2}, Angelina Tjokrowidjaja^{3

4}, Craig Lewis^{5

6}, Jodi Lynch³

Affiliations

¹ Department of Haematology, Dubbo Hospital, Dubbo, New South Wales, Australia.
² Dubbo Hospital Laboratory, NSW Health Pathology, New South Wales, Dubbo, Australia.
³ Department of Medical Oncology, St George Hospital, Sydney, New South Wales, Australia.
⁴ National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
⁵ Department of Medical Oncology, Prince of Wales Hospital and Community Health Services, New South Wales, Sydney, Australia.
⁶ Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.

PMID: 36693646
DOI: 10.1111/imj.15984

Abstract

Venous thromboembolism (VTE) has a significant adverse impact on the outcomes of patients with active solid malignancies. Prophylaxis is indicated for cancer-associated VTE (CA-VTE) using the Khorana score for risk stratification. We surveyed medical oncology fellows and trainees regarding their practice in CA-VTE. Regarding treatment of CA-VTE, practice was consistent with guidelines. However, regarding prophylaxis for CA-VTE, there was a high degree of uncertainty, which highlights the need for ongoing education.

Keywords: VTE prophylaxis; VTE treatment; cancer-associated venous thromboembolism.

MeSH terms

Anticoagulants / therapeutic use
Humans
Neoplasms* / drug therapy
Neoplasms* / therapy
Oncologists*
Risk Factors
Surveys and Questionnaires
Venous Thromboembolism* / drug therapy
Venous Thromboembolism* / prevention & control

Substances

Anticoagulants